- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Oncology
Volume 2012 (2012), Article ID 204593, 7 pages
The Role of FoxC2 Transcription Factor in Tumor Angiogenesis
Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Northwestern University, 303E Chicago Avenue, Chicago, IL 60611, USA
Received 27 May 2011; Revised 17 August 2011; Accepted 29 August 2011
Academic Editor: Debabrata Mukhopadhyay
Copyright © 2012 Tsutomu Kume. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Much has been learned about the mechanisms underlying tumor angiogenesis, and therapies that target vascular endothelial growth factor (VEGF) to limit tumor angiogenesis and subsequent disease progression have recently been approved. However, the transcriptional mechanisms that regulate pathological angiogenesis remain largely unknown. FoxC2, a member of the Forkhead box (Fox) transcription factor family, is critical for vascular formation during development, and recent studies have shown that FoxC2 is expressed in the endothelium of tumors in both humans and mice. In a B16 mouse melanoma model, Foxc2 deficiency reduced tumor growth and neovascularization and was associated with impairments in mural-cell coverage and increases in endothelial-cell apoptosis in tumor blood vessels. FoxC2 is also expressed by tumor cells in human breast, colonic, and esophageal cancer and participates in the epithelial-mesenchymal transition (EMT), a key process that leads to the invasion and metastasis of aggressive tumors. Collectively, these observations suggest that FoxC2 is essential for tumor angiogenesis and disease progression and that FoxC2 may be a viable target for cancer therapy.
Tumor angiogenesis is a crucial contributor to tumor development and progression  because tumor blood vessels supply oxygen and nutrients to the tumor tissue and facilitate cancer cell invasion and metastasis. Tumor vessels are usually disorganized and excessively branched [2–4], and formation of the tumor vasculature involves complex interactions between tumor cells and their microenvironment that are controlled by numerous angiogenic factors secreted from both tumor cells and other cells in the tumor microenvironment. The mechanisms by which proangiogenic factors such as vascular endothelial growth factor (VEGF) promote tumor angiogenesis have been intensively studied [2–4]; however, the transcription factors that participate in this process remain incompletely understood. The FoxC2 transcription factor is a newly recognized regulator of tumor angiogenesis and metastasis, and this paper summarizes what is currently known about the role of FoxC2 in cancer.
2. Forkhead Transcription Factors in Cancer
The Fox (Forkhead box) transcription factors form a large family of proteins with similar DNA-binding domains that are evolutionarily conserved from yeast to humans [5–7]; other functional regions of Fox proteins, such as the transactivation and transrepression domains, are largely divergent. The consensus, seven-nucleotide core sequence bound by monomeric Fox proteins is 5′-(G/A)(T/C)(A/C)AA(C/T)A-3′ [8, 9], and Fox proteins are distributed among 19 subfamilies (FoxA to FoxS) based on similarities in their DNA-binding domains. Uppercase letters are used to designate human Fox genes (e.g., FoxC2), the first letter is capitalized for mouse genes (e.g., FoxC2), and the first and subclass letters are capitalized for chordates (e.g., FoxC2).
Fox proteins have many essential roles in embryonic development, and the mutation or dysregulation of FOX genes is often associated with disease, including cancer . FoxM1 is expressed in glioma and pancreatic cancer cells and promotes angiogenesis by regulating VEGF expression [11, 12], FoxO1/3/4 act as tumor suppressors in prostate cancer and leukemia [13, 14], and recent evidence suggests that FoxC2 is a key factor in tumor development and disease progression. Thus, the elucidation of FOX gene function will likely identify new strategies for the treatment of cancer.
3. Role of FoxC2 in Vascular Development and Angiogenesis
Murine FoxC2 is highly expressed in blood endothelial cells during embryonic development [16–19]. FoxC2 contributes to arterial cell specification in the early developing embryo as a downstream regulator of the Notch signaling pathway [18, 20–22], and FoxC2 participates in angiogenesis [23, 24] through the activity of its downstream targets CXC-chemokine receptor 4 (CXCR4) and integrin 3 [25, 26]. The transcriptional activity of FoxC2 in vascular endothelial cells is modulated by VEGF signaling , and FoxC2 is critical for the migration of endothelial cells toward VEGF or stromal-cell-derived factor 1 (SDF-1) and for the formation of microvessels in vitro [25, 26]. Recent studies have shown that the activity of FoxC2 and the Ets transcription factor Etv2 combine to regulate endothelial-specific gene expression during early development, including Flk1, Tie2, and VE-cadherin , and the Ets transcription factors are known to be important for tumor angiogenesis , but whether FoxC2 and Etv2 also coregulate tumor vessel formation has yet to be determined.
The importance of epigenetic changes during the regulation of angiogenesis, including the methylation or histone acetylation of angiogenesis-associated genes, is becoming increasingly apparent ; for example, the histone deacetylase (HDAC) SIRT1 induces the sprouting and branching of endothelial cells by deacetylating Foxo1 . SIRT1 also regulates the angiogenic activity of endothelial cells by deacetylating the Notch1 intracellular domain (NICD) , and a Notch transcriptional activation complex containing the NICD physically and functionally interacts with FoxC2 . Collectively, these observations suggest that FoxC2 may be involved in SIRT1-mediated transcriptional control of angiogenesis.
FoxC2 is also expressed in lymphatic endothelial cells during development [32, 33], and mutations in human FoxC2 are responsible for the autosomal dominant syndrome lymphedema distichiasis, which is characterized by the obstruction of lymph drainage in the limbs and by the growth of an extra set of eyelashes [34, 35]. Congenital lymphatic defects are also observed in FoxC2 mutant mice: heterozygous FoxC2 mutants display hyperplasia of the lymphatic vessels , and homozygous FoxC2 mutants have defective lymphatic valves and abnormal pericyte recruitment of lymphatic vessels . The contribution of FoxC2 to lymphangiogenesis in pathological conditions such as cancer remains unknown.
4. FoxC2 in Tumor Angiogenesis
FoxC2 expression has been detected in the tumor endothelium of both human and mouse melanomas, which suggests that FoxC2 has a role in tumor angiogenesis (Table 1) . Homozygous mutations of FoxC2 lead to perinatal lethality, so the role of FoxC2 in melanoma was confirmed by subcutaneously implanting mouse B16 melanoma cells in wild-type and heterozygous FoxC2 mutant (FoxC2+/–) mice. Tumor growth and angiogenesis were remarkably lower in the FoxC2+/– mutants (Figure 1) , which confirms that FoxC2 has an essential role in tumor angiogenesis. Matrix metalloproteinase (MMP) 2 expression was also diminished in B16 tumors from FoxC2+/– mice , which is consistent with evidence that MMP2 is important for tumor growth and angiogenesis [37, 38]. The expression of the lymphatic endothelial markers Prox1 and Lyve1 were unchanged , despite evidence that FoxC2 is expressed in lymphatic endothelial cells.
VEGF-A expression was also impaired in B16 tumors from FoxC2+/– mice , and this decline likely limits tumor neovascularization. The cells responsible for the decline in VEGF-A expression have yet to be identified; however, autocrine VEGF signaling promotes endothelial cell survival , and smooth muscle α-actin- (αSMA-) positive cancer-associated fibroblasts (CAFs), which are known to express VEGF-A in the tumor microenvironment [43–45], were less common in tumors from FoxC2+/– mice than in tumors from wild-type mice . CAFs also secrete stromal cell-derived factor 1 (SDF-1), which stimulates tumor growth by activating its receptor, CXCR4, on tumor cells and by functioning as a chemoattractant for the recruitment of bone-marrow-derived endothelial progenitor cells that subsequently promote angiogenesis . FoxC2 is also known to regulate the CXCR4-dependent mobilization of endothelial cells and bone-marrow-derived endothelial progenitor cells [25, 46], so FoxC2 might have a bimodal influence on the contribution of bone-marrow-derived cells to tumor angiogenesis by increasing both cell mobilization and the SDF-1-mediated recruitment of mobilized cells to tumors. Furthermore, FoxC2 expression is induced by hypoxia after ischemia/reperfusion injury in the kidney , and the hypoxic gradient that develops in the tumor microenvironment increases SDF-1 expression in CAFs and CXCR4 expression in tumor cells [48, 49]; thus, FoxC2 could also contribute to tumor angiogenesis through a hypoxia-related mechanism.
Fibroblasts in the tumor microenvironment are a heterogeneous cell population, and the conventional markers SMA and vimentin cannot identify all CAFs . Furthermore, transforming growth factor- (TGF-)1 can induce the phenotypic conversion of proliferating vascular endothelial cells into fibroblast-like cells; this endothelial-to-mesenchymal transition (EndMT) takes place at the invasive front of tumors in mice , and, consequently, antiangiogenic treatments may limit cancer progression, in part, by directly influencing the EndMT in tumor vessels. The molecular mechanisms and signaling pathways that control EndMT have yet to be elucidated; however, CAFs can develop directly from cancer cells through the epithelial-to-mesenchymal transition (EMT) , which is regulated by FoxC2 (as discussed in the next section). CAFs can also evolve from resident fibroblasts, smooth muscle cells, pericytes, or bone-marrow-derived mesenchymal stem cells through a mesenchymal-to-mesenchymal transition (MMT), which is regulated by tumor-cell-derived factors such as TGF-, platelet-derived growth factor (PDGF), and basic fibroblast growth factor (FGF) ; whether FoxC2 participates in the MMT is unknown.
The declines in tumor growth and vascularity observed in FoxC2+/– mice were also associated with abnormally low levels of PDGF-B, which is likely attributable to the impaired growth of smooth muscle cells surrounding the tumor blood vessels . The precise role of PDGF signaling in tumor angiogenesis remains a subject of debate ; however, PDGF mediates the maturation and stabilization of blood vessels during normal vessel growth by regulating the interaction between endothelial cells and mural cells (e.g., vascular smooth muscle cells and pericytes) that are loosely associated with the tumor endothelium, and PDGF-B inhibition is associated with both the loss of mural cells and tumor-vessel regression . The blockade of both VEGF and PDGF receptor- signaling in tumor blood vessels with kinase inhibitors also induces tumor vessel regression [56, 57], and paracrine signaling between pericytes and the tumor endothelium  could increase the instability of the tumor vessels of FoxC2+/– mice by reducing VEGF and PDGF-B signaling .
5. FoxC2 in Cancer Cells
Tumor FoxC2 expression is not restricted to the vasculature (Table 1) . T-MTA-6A tissue-array (NCI/NIH) analysis revealed the localization of FoxC2 protein in the majority of breast adenocarcinomas, including lobular and ductal adenocarcinoma, and in about half of colonic adenocarcinomas . FoxC2 expression has also been reported in esophageal cancer cells , and the survival rate is significantly lower for patients with high levels of FoxC2 expression than for patients with low levels of FoxC2 expression, which suggests that FoxC2 could be used as a novel, independent prognosis factor for patients with esophageal cancer  (Table 1). Patients with high levels of FoxC2 expression also have higher levels of MMP2 and MMP9 expression .
FoxC2 is an important regulator of EMT, a key process that is often activated during tumor progression and metastasis . FoxC2 expression is significantly correlated with highly aggressive basal-like breast cancers, and FoxC2 overexpression increases the metastatic potential of mouse mammary carcinoma cells to the lung . The EMT-inducing transcription factors Twist, Snail, and Goosecoid, as well as TGF-, which also induces EMT, can induce FoxC2 expression in epithelial cells [40, 60], and FoxC2 overexpression promotes mesenchymal differentiation, as well as the induction of MMP2 and MMP9 expression . Furthermore, FoxC2 indirectly represses expression of the epithelial marker E-cadherin, whose loss is considered a hallmark of EMT , and directly downregulates p120-catenin, a regulatory protein that stabilizes E-cadherin at the adhesion junctions of epithelial cells . Thus, accumulating evidence indicates that EMT-inductive signaling molecules, such as TGF-, stimulate FoxC2 expression in carcinoma cells along with other EMT-promoting transcription factors and mediates mesenchymal differentiation, thereby leading to EMT and metastasis . EMT has also been linked to the genesis of cancer stem cells ; for example, mammary epithelial cells have been shown to acquire properties associated with breast cancer stem cells, including the signature, after undergoing EMT and to express EMT-inducing transcription factors such as FoxC2 (Table 1) . Notably, tumor cells undergoing EMT acquire a migratory phenotype by ectopically expressing mesenchymal genes, including FoxC2, which first function in the developing embryo, and tumor cells may adopt many other developmental signaling pathways that function in their ancestral precursor cells [63–65]. Thus, EMT may represent a critical point of convergence between the signaling paradigms that regulate development and tumor metastasis.
6. Future Perspectives
Though we are just beginning to understand how FoxC2 contributes to cancer development and related pathological conditions, its newly discovered role in tumor angiogenesis and metastasis suggests that FoxC2 could be an intriguing target for anticancer therapies. Drug therapies rarely target transcription factors directly, but a combination of advanced technologies, such as systems biology and computational chemistry, could lead to the development of viable transcriptional approaches for preventing cancer development and progression, as well as other conditions that involve pathological angiogenesis. For example, FoxM1 is currently being investigated as a target for cancer therapy , and several chemical inhibitors, including proteasome inhibitors, of FoxM1 have been reported [67–71], as well as a cell-penetrating peptide inhibitor of FoxM1 function . The precise function of FoxC2 in the tumor microenvironment, including both cancer cells and endothelial cells, must be better understood before the development of FoxC2-based therapies can be considered and, consequently, studies focusing on the mechanisms controlled by FoxC2 are necessary. The identification of relatively small peptides that can selectively block the function of FoxC2 would also be a useful step toward designing FoxC2-specific inhibitors.
The author thanks W. Kevin Meisner, Ph.D., ELS, for editorial support. This work was supported by NIH grants (HL074121 and EY019484) to the author.
- D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000.
- P. Carmeliet, “Angiogenesis in life, disease and medicine,” Nature, vol. 438, no. 7070, pp. 932–936, 2005.
- N. Ferrara and R. S. Kerbel, “Angiogenesis as a therapeutic target,” Nature, vol. 438, no. 7070, pp. 967–974, 2005.
- D. M. McDonald and P. L. Choyke, “Imaging of angiogenesis: from microscope to clinic,” Nature Medicine, vol. 9, no. 6, pp. 713–725, 2003.
- K. H. Kaestner, W. Knöchel, and D. E. Martínez, “Unified nomenclature for the winged helix/forkhead transcription factors,” Genes and Development, vol. 14, no. 2, pp. 142–146, 2000.
- S. M. Shimeld, B. Degnan, and G. N. Luke, “Evolutionary genomics of the Fox genes: origin of gene families and the ancestry of gene clusters,” Genomics, vol. 95, no. 5, pp. 256–260, 2010.
- K. R. Wotton and S. M. Shimeld, “Comparative genomics of vertebrate Fox cluster loci,” BMC Genomics, vol. 7, article 271, 2006.
- P. Carlsson and M. Mahlapuu, “Forkhead transcription factors: key players in development and metabolism,” Developmental Biology, vol. 250, no. 1, pp. 1–23, 2002.
- E. Kaufmann and W. Knöchel, “Five years on the wings of fork head,” Mechanisms of Development, vol. 57, no. 1, pp. 3–20, 1996.
- S. S. Myatt and E. W. Lam, “The emerging roles of forkhead box (Fox) proteins in cancer,” Nature Reviews Cancer, vol. 7, no. 11, pp. 847–859, 2007.
- Z. Wang, S. Banerjee, D. Kong, Y. Li, and F. H. Sarkar, “Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells,” Cancer Research, vol. 67, no. 17, pp. 8293–8300, 2007.
- Y. Zhang, N. Zhang, B. Dai et al., “FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells,” Cancer Research, vol. 68, no. 21, pp. 8733–8742, 2008.
- X. Y. Dong, C. Chen, X. Sun et al., “FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer,” Cancer Research, vol. 66, no. 14, pp. 6998–7006, 2006.
- J. H. Paik, R. Kollipara, G. Chu et al., “FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis,” Cell, vol. 128, no. 2, pp. 309–323, 2007.
- H. Sano, J. P. LeBoeuf, S. V. Novitskiy et al., “The FoxC2 transcription factor regulates tumor angiogenesis,” Biochemical and Biophysical Research Communications, vol. 392, no. 2, pp. 201–206, 2010.
- K. Iida, H. Koseki, H. Kakinuma et al., “Essential roles of the winged helix transcription factor MFH-1 in aortic arch patterning and skeletogenesis,” Development, vol. 124, no. 22, pp. 4627–4638, 1997.
- T. Kume, H. Jiang, J. M. Topczewska, and B. L. Hogan, “The murine winged helix transcription factors, Foxc1 and FoxC2, are both required for cardiovascular development and somitogenesis,” Genes and Development, vol. 15, no. 18, pp. 2470–2482, 2001.
- S. Seo, H. Fujita, A. Nakano, M. Kang, A. Duarte, and T. Kume, “The forkhead transcription factors, Foxc1 and FoxC2, are required for arterial specification and lymphatic sprouting during vascular development,” Developmental Biology, vol. 294, no. 2, pp. 458–470, 2006.
- G. E. Winnier, T. Kume, K. Deng et al., “Roles for the winged helix transcription factors MF1 and MFH1 in cardiovascular development revealed by nonallelic noncomplementation of null alleles,” Developmental Biology, vol. 213, no. 2, pp. 418–431, 1999.
- H. Hayashi and T. Kume, “Foxc transcription factors directly regulate DII4 and hey2 expression by interacting with the VEGF-notch signaling pathways in endothelial cells,” PLoS ONE, vol. 3, no. 6, Article ID e2401, 2008.
- T. Kume, “The cooperative roles of Foxc1 and FoxC2 in cardiovascular development,” Advances in Experimental Medicine and Biology, vol. 665, pp. 63–77, 2009.
- K. N. Papanicolaou, Y. Izumiya, and K. Walsh, “Forkhead transcription factors and cardiovascular biology,” Circulation Research, vol. 102, no. 1, pp. 16–31, 2008.
- H. Hayashi and T. Kume, “FoxC2 transcription factor as a regulator of angiogenesis via induction of integrin β3 expression,” Cell Adhesion and Migration, vol. 3, no. 1, pp. 24–26, 2009.
- T. Kume, “FoxC2 transcription factor: a newly described regulator of angiogenesis,” Trends in Cardiovascular Medicine, vol. 18, no. 6, pp. 224–228, 2008.
- H. Hayashi and T. Kume, “Forkhead transcription factors regulate expression of the chemokine receptor CXCR4 in endothelial cells and CXCL12-induced cell migration,” Biochemical and Biophysical Research Communications, vol. 367, no. 3, pp. 584–589, 2008.
- H. Hayashi, H. Sano, S. Seo, and T. Kume, “The FoxC2 transcription factor regulates angiogenesis via induction of integrin β3 expression,” Journal of Biological Chemistry, vol. 283, no. 35, pp. 23791–23800, 2008.
- S. de Val, N. C. Chi, S. M. Meadows et al., “Combinatorial regulation of endothelial gene expression by ets and forkhead transcription factors,” Cell, vol. 135, no. 6, pp. 1053–1064, 2008.
- P. Oettgen, “The role of ets factors in tumor angiogenesis,” Journal of Oncology, vol. 2010, Article ID 767384, 6 pages, 2010.
- I. Buysschaert, T. Schmidt, C. Roncal, P. Carmeliet, and D. Lambrechts, “Genetics, epigenetics and pharmaco-(epi)genomics,” Journal of Cellular and Molecular Medicine, vol. 12, no. 6B, pp. 2533–2551, 2008.
- M. Potente, L. Ghaeni, D. Baldessari et al., “SIRT1 controls endothelial angiogenic functions during vascular growth,” Genes and Development, vol. 21, no. 20, pp. 2644–2658, 2007.
- V. Guarani, G. Deflorian, C. A. Franco et al., “Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase,” Nature, vol. 473, no. 7346, pp. 234–238, 2011.
- S. L. Dagenais, R. L. Hartsough, R. P. Erickson, M. H. Witte, M. G. Butler, and T. W. Glover, “FoxC2 is expressed in developing lymphatic vessels and other tissues associated with lymphedema-distichiasis syndrome,” Gene Expression Patterns, vol. 4, no. 6, pp. 611–619, 2004.
- T. V. Petrova, T. Karpanen, C. Norrmén et al., “Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis,” Nature Medicine, vol. 10, no. 9, pp. 974–981, 2004.
- J. Fang, S. L. Dagenais, R. P. Erickson et al., “Mutations in FoxC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome,” American Journal of Human Genetics, vol. 67, no. 6, pp. 1382–1388, 2000.
- T. Mäkinen, C. Norrmén, and T. V. Petrova, “Molecular mechanisms of lymphatic vascular development,” Cellular and Molecular Life Sciences, vol. 64, no. 15, pp. 1915–1929, 2007.
- B. M. Kriederman, T. L. Myloyde, M. H. Witte et al., “FoxC2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome,” Human Molecular Genetics, vol. 12, no. 10, pp. 1179–1185, 2003.
- T. Itoh, M. Tanioka, H. Yoshida, T. Yoshioka, H. Nishimoto, and S. Itohara, “Reduced angiogenesis and tumor progression in gelatinase A-deficient mice,” Cancer Research, vol. 58, no. 5, pp. 1048–1051, 1998.
- K. Taniwaki, H. Fukamachi, K. Komori et al., “Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice,” Cancer Research, vol. 67, no. 9, pp. 4311–4319, 2007.
- N. Nishida, K. Mimori, T. Yokobori et al., “FoxC2 is a novel prognostic factor in human esophageal squamous cell carcinoma,” Annals of Surgical Oncology, pp. 1–8, 2010.
- S. A. Mani, J. Yang, M. Brooks et al., “Mesenchyme Forkhead 1 (FoxC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 24, pp. 10069–10074, 2007.
- S. A. Mani, W. Guo, M. J. Liao et al., “The epithelial-mesenchymal transition generates cells with properties of stem cells,” Cell, vol. 133, no. 4, pp. 704–715, 2008.
- S. Lee, T. T. Chen, C. L. Barber et al., “Autocrine VEGF signaling is required for vascular homeostasis,” Cell, vol. 130, no. 4, pp. 691–703, 2007.
- N. Ferrara, “Pathways mediating VEGF-independent tumor angiogenesis,” Cytokine and Growth Factor Reviews, vol. 21, no. 1, pp. 21–26, 2010.
- D. Fukumura, R. Xavier, T. Sugiura et al., “Tumor induction of VEGF promoter activity in stromal cells,” Cell, vol. 94, no. 6, pp. 715–725, 1998.
- A. Orimo, P. B. Gupta, D. C. Sgroi et al., “Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion,” Cell, vol. 121, no. 3, pp. 335–348, 2005.
- D. Li, D. Yan, W. Liu et al., “FoxC2 overexpression enhances benefit of endothelial progenitor cells for inhibiting neointimal formation by promoting CXCR4-dependent homing,” Journal of Vascular Surgery, vol. 53, no. 6, pp. 1668–1678, 2011.
- C. Hader, A. Marlier, and L. Cantley, “Mesenchymal-epithelial transition in epithelial response to injury: the role of FoxC2,” Oncogene, vol. 29, no. 7, pp. 1031–1040, 2010.
- J. A. Burger and T. J. Kipps, “CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment,” Blood, vol. 107, no. 5, pp. 1761–1767, 2006.
- Q. Lin and Z. Yun, “Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics,” Cancer Biology and Therapy, vol. 9, no. 12, pp. 949–956, 2010.
- H. Sugimoto, T. M. Mundel, M. W. Kieran, and R. Kalluri, “Identification of fibroblast heterogeneity in the tumor microenvironment,” Cancer Biology and Therapy, vol. 5, no. 12, pp. 1640–1646, 2006.
- E. M. Zeisberg, S. Potenta, L. Xie, M. Zeisberg, and R. Kalluri, “Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts,” Cancer Research, vol. 67, no. 21, pp. 10123–10128, 2007.
- R. Kalluri and M. Zeisberg, “Fibroblasts in cancer,” Nature Reviews Cancer, vol. 6, no. 5, pp. 392–401, 2006.
- G. Xouri and S. Christian, “Origin and function of tumor stroma fibroblasts,” Seminars in Cell and Developmental Biology, vol. 21, no. 1, pp. 40–46, 2010.
- J. Andrae, R. Gallini, and C. Betsholtz, “Role of platelet-derived growth factors in physiology and medicine,” Genes and Development, vol. 22, no. 10, pp. 1276–1312, 2008.
- B. Sennino, B. L. Falcón, D. McCauley et al., “Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102,” Cancer Research, vol. 67, no. 15, pp. 7358–7367, 2007.
- R. Erber, A. Thurnher, A. D. Katsen et al., “Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms,” The FASEB Journal, vol. 18, no. 2, pp. 338–340, 2004.
- O. Potapova, A. D. Laird, M. A. Nannini et al., “Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248,” Molecular Cancer Therapeutics, vol. 5, no. 5, pp. 1280–1289, 2006.
- P. Guo, B. Hu, W. Gu et al., “Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment,” American Journal of Pathology, vol. 162, no. 4, pp. 1083–1093, 2003.
- J. Yang and R. A. Weinberg, “Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis,” Developmental Cell, vol. 14, no. 6, pp. 818–829, 2008.
- L. E. Lindley and K. J. Briegel, “Molecular characterization of TGFbeta-induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells,” Biochemical and Biophysical Research Communications, vol. 399, no. 4, pp. 659–664, 2010.
- F. Mortazavi, J. An, S. Dubinett, and M. Rettig, “p120-Catenin is transcriptionally downregulated by FoxC2 in non-small cell lung cancer cells,” Molecular Cancer Research, vol. 8, no. 5, pp. 762–774, 2010.
- J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, “Epithelial-mesenchymal transitions in development and disease,” Cell, vol. 139, no. 5, pp. 871–890, 2009.
- L. A. Garraway and W. R. Sellers, “Lineage dependency and lineage-survival oncogenes in human cancer,” Nature Reviews Cancer, vol. 6, no. 8, pp. 593–602, 2006.
- P. B. Gupta, C. Kuperwasser, J. P. Brunet et al., “The melanocyte differentiation program predisposes to metastasis after neoplastic transformation,” Nature Genetics, vol. 37, no. 10, pp. 1047–1054, 2005.
- R. N. Johnston, S. B. Pai, and R. B. Pai, “The origin of the cancer cell: oncogeny reverses phylogeny,” Biochemistry and Cell Biology, vol. 70, no. 10-11, pp. 831–834, 1992.
- Z. Wang, A. Ahmad, Y. Li, S. Banerjee, D. Kong, and F. H. Sarkar, “Forkhead box M1 transcription factor: a novel target for cancer therapy,” Cancer Treatment Reviews, vol. 36, no. 2, pp. 151–156, 2010.
- U. G. Bhat, M. Halasi, and A. L. Gartel, “FoxM1 is a general target for proteasome inhibitors,” PLoS ONE, vol. 4, no. 8, Article ID e6593, 2009.
- U. G. Bhat, M. Halasi, and A. L. Gartel, “Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells,” PLoS ONE, vol. 4, no. 5, Article ID e5592, 2009.
- Y. Li, X. Hong, M. Hussain, S. H. Sarkar, R. Li, and F. H. Sarkar, “Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells,” Molecular Cancer Therapeutics, vol. 4, no. 3, pp. 389–398, 2005.
- Y. Li, M. Hussain, S. H. Sarkar, J. Eliason, R. Li, and F. H. Sarkar, “Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells,” BMC Cancer, vol. 5, article 7, 2005.
- S. K. Radhakrishnan, U. G. Bhat, D. E. Hughes, I. C. Wang, R. H. Costa, and A. L. Gartel, “Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1,” Cancer Research, vol. 66, no. 19, pp. 9731–9735, 2006.
- G. A. Gusarova, I. C. Wang, M. L. Major et al., “A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 99–111, 2007.